US Patent 9,357,783 Claim Scope for 5,5′-Dimethyl-2,2′-Dipyridyl Topical Ectoparasitic Compositions: What’s Covered, What’s Not, and How Competitive Entry Works
US Drug Patent 9,357,783 claims topical compositions built around 5,5′-dimethyl-2,2′-dipyridyl (and salts), with coverage shaped by (i) delivery form, (ii) target anatomy/use (skin, scalp), (iii) concentration windows, and (iv) combination inclusion with a second ectoparasiticide. Infringement risk concentrates on products that put the claimed active into topically applied dosage forms including shampoos and lotions, at concentrations that fall inside the specified ranges, and (for claim 9) combinations that include another ectoparasiticide that addresses nymphs and/or adult ectoparasites.
The patent landscape implications for a competitor are straightforward: design around by moving outside the defined topical forms, the concentration claim windows, the combination structure, and/or the specific “treat or prevent ectoparasite infestation” functional language. For licensing and enforcement, the claims are structured so the patent holder can pursue both single-agent and combination topical products, with the strongest leverage in shampoo/lotion/scalp use and in actives/formulations that track the numeric concentration ranges.
What does US Patent 9,357,783 claim for topical compositions of 5,5′-dimethyl-2,2′-dipyridyl?
Core active and claim baseline
Across the independent claim (claim 1) and related dependent claims (12), the patent’s center of gravity is:
- Active: 5,5′-dimethyl-2,2′-dipyridyl
- Also covered: pharmaceutically, veterinary, or agriculturally acceptable salts
- Required presentation: formulated for topical application
- Delivery forms: one of the listed topical dosage categories:
- dip, spray, aerosol, shampoo, mousse, emulsion, foam, cream, dust, gel, lotion
This baseline means the claim is not limited to a specific ectoparasite species on its face (in claim 1). The functional “treat or prevent ectoparasite infestation” language appears explicitly in claim 12.
Claim 1 is a “broad topical form coverage” independent
Claim 1 reads as a composition claim with:
- a defined chemical identity (active or salt)
- a defined route and product form (topical, selected from the dosage-form list)
- no explicit concentration on claim 1 itself (numeric constraints appear in dependent claims 5–8)
This is a classic enforcement posture: if a topical product contains the active/salt in any of the listed dosage forms, the claimant can argue coverage even before numeric concentration is needed, unless the claim is narrowed by dependent-claim concentration limitations in the asserted theory.
Which topical dosage forms are explicitly included, and how does that constrain design-around?
Included dosage forms (claim 1 and claim 12)
The patent enumerates the form options as a closed group:
- dip
- spray
- aerosol
- shampoo
- mousse
- emulsion
- foam
- cream
- dust
- gel
- lotion
Constrain points for competitors
A design-around strategy must address the “form selected from the group consisting of…” construction. If a competitor uses an uncaptured vehicle form, the patent holder can still argue functional equivalence depending on claim construction, but the legal hook is the enumerated list.
In practical product design terms, products marketed as:
- shampoo or lotion are directly called out multiple times (claims 4 and 11 and claim 13), tightening both marketing-to-claim fit and evidentiary pathways.
- sprays/aerosols/gels/creams/foams/emulsions are also directly inside the claim.
Does US 9,357,783 cover skin-only or scalp-specific formulations?
Skin limitation (claim 2)
Claim 2 narrows claim 1 to:
- composition formulated for application to skin
This is a dependent limitation. A competitor selling a topical product that is not “for application to skin” (for example, a non-skin route or a device-mediated use framed outside skin application) aims to avoid this dependent claim, while still potentially falling under claim 1 unless other limitations are met.
Scalp limitation (claim 3)
Claim 3 tightens claim 2 to:
- formulated for application to the human scalp
This is commercially important because scalp-directed products (anti-lice, anti-scalp ectoparasites) are commonly sold in shampoo and lotion/solution formats, matching claims 4 and 11 and 13.
For infringement posture, scalp labeling and instructions for human use can become key evidence. It also increases litigation leverage if competitors market to human scalp rather than only to animals.
What concentration ranges of 5,5′-dimethyl-2,2′-dipyridyl are covered?
The patent uses multiple dependent claims to create discrete numeric windows. These matter because they give multiple “landing pads” for infringement arguments based on product composition.
Concentration dependent claims under claim 1 (claims 5–8)
Each depends on claim 1.
- Claim 5: concentration between 0.0001 mM and 1 M
- Claim 6: concentration between 0.01 mM and 100 mM
- Claim 7: concentration between 0.1 mM and 30 mM
- Claim 8: concentration between 5 mM and 15 mM
These ranges nest within each other. Claim 5 is the widest; claim 8 is the tightest.
Concentration dependent claims under claim 12 (claims 14–16)
Each depends on claim 12.
- Claim 14: 0.01 mM to 100 mM
- Claim 15: 0.1 mM to 30 mM
- Claim 16: 5 mM to 15 mM
How numeric windows shape entry risk
For a competitor, the “safe” zone is outside the numeric limitations of whichever claim is asserted:
- If the patent holder asserts claim 1 (no numeric range), concentration is not needed.
- If numeric constraints are required in a particular infringement theory or claim set, then staying outside the windows becomes relevant.
Because multiple nested concentration ranges exist, a common “low dose” or “mid dose” formulation may still land in at least one dependent range. The highest certainty design-around is to operate outside all asserted numeric windows while also avoiding the claim’s other structural elements (topical form, scalp/skin context, and second ectoparasiticide combination in claim 9).
What combination products are covered, and what second ingredient is required by claim 9?
Claim 9 extends claim 1 with a second ectoparasiticide
Claim 9 requires:
- (i) 5,5′-dimethyl-2,2′-dipyridyl (or salt) and
- (ii) a second ectoparasiticide
- formulated for topical application
- and formulated in one of the enumerated topical forms (same list as claim 1)
Additional functional limitation for nymph/adult ectoparasites (claim 10)
Claim 10 narrows claim 9 to situations where:
- the second ectoparasiticide controls nymphs and/or adult ectoparasites
This is a functional coverage element tied to the second ingredient’s claimed biological effect. For enforcement, the second ingredient’s label indications, preclinical data, or marketing claims can matter.
How strong is the patent’s coverage for “treat or prevent ectoparasite infestation” products?
Claim 12 adds a treatment/prevention function
Claim 12 requires:
- a composition consisting of 5,5′-dimethyl-2,2′-dipyridyl (or salt)
- formulated for topical application in one of the enumerated forms
- includes an effective amount of the active
- used to treat or prevent ectoparasite infestation
This claim is narrower than claim 1 in two ways:
- it is explicitly limited by the treat/prevent functional requirement
- it uses the wording “consisting of” for the parasiticide composition element (which can be important for composition-in-combination arguments). Based on the claim text you provided, claim 12 appears to require that the parasiticide component is composed of the active/salt, even if the formulation contains carriers/excipients.
Shampoo/lotion direct application (claim 13)
Claim 13 adds:
- direct topical application in the form of shampoo or lotion
This is a direct commercial alignment with scalp/skin ectoparasite products.
Is US 9,357,783 limited to human use, or does it cover veterinary and agricultural use too?
Salt acceptability includes multiple domains
The claim language explicitly includes:
- pharmaceutically, veterinary, or agriculturally acceptable salts
So the salt acceptability is multi-domain. However, specific dependent claims narrow to:
- application to the human scalp (claim 3)
- treatment/prevention of ectoparasite infestation is general in claim 12, not explicitly limited to humans.
From a claim construction perspective, this means the patent holder has a route to enforcement for veterinary products that match claim 1 or 12 structures, even if the scalp-specific dependent claim is human-only.
What is the likely infringement “claim chart” for a shampoo product?
Typical shampoo fact pattern mapping
A competitor product description that aligns with the patent will usually include:
- Contains 5,5′-dimethyl-2,2′-dipyridyl (or a claimed acceptable salt)
- Is marketed for topical application
- Product form is shampoo
- Instructions are for skin or human scalp (for claim 3)
- Concentration matches one of the dependent ranges (claims 5–8 or 14–16)
- If combination: includes another ectoparasiticide that controls nymphs and/or adults (claims 9–10)
- If single-agent therapeutic framing: includes effective amount to treat/prevent ectoparasite infestation (claims 12–13)
Most assertable combinations
- Broadest claim entry point: claim 1 (topical composition in listed forms)
- Most commercially aligned: claim 4/13 (shampoo or lotion), claim 3 (human scalp)
- Numeric leverage: claim 8 (5 mM to 15 mM) is the narrowest and typically the easiest to prove if the product matches a reported active concentration.
How many distinct claim “buckets” create coverage pathways?
From the provided claims alone, there are at least these separable coverage buckets:
- Single-agent topical composition: claim 1 (with dependent ranges 5–8 and skin/scalp/form add-ons 2–4)
- Treatment/prevention single-agent: claim 12 (with dependent ranges 14–16 and shampoo/lotion add-on 13)
- Combination topical composition: claim 9 (with nymph/adult functional limitation 10)
Each bucket supports an infringement theory that can be selected based on how a competitor’s product is formulated and marketed.
What would a competitor change to avoid each major claim bucket?
To avoid claim 1 (topical composition in enumerated forms)
- Remove the active/salt entirely, or use a non-salt form outside “acceptable salt” arguments (highly fact-dependent but is the only structural path in the claim you provided)
- Re-engineer the product form so it is not marketed or constructed as one of the enumerated dosage categories (risk remains because claims say “selected from,” but the form-list is not open-ended)
- If asserted via dependent claims, avoid skin/scalp targeting (claim 2/3) and/or avoid the shampoo/lotion form if narrowed through dependent claims 4/11/13
To avoid concentration-based dependent claims (5–8, 14–16)
- Adjust active concentration so it falls outside the asserted ranges.
- Because multiple nested ranges exist, “just under” one window may still fall inside a broader one. The safest engineering is to keep outside all windows that are plausibly asserted (with the understanding that claim 1 itself has no concentration limitation in your claim text, so this helps only if claim 1 is not the asserted hook).
To avoid claim 9/10 combination coverage
- Eliminate the second ectoparasiticide
- Or ensure the second ingredient does not meet “controls nymphs and/or adult ectoparasites” as a functional coverage requirement (this depends on how biological control claims are supported and marketed)
How does US 9,357,783 compare with typical ectoparasiticide IP strategy?
This patent fits the common structure for dermatology/parasiticide compositions:
- Chemical identity anchored at a defined active
- Route of administration anchored at topical application
- Product-form list for “dosage form” coverage
- Narrow dependent claims for numeric concentration and for a specific anatomical target (human scalp)
- A combination-dependent claim tied to inclusion of a second ectoparasiticide with developmental-stage effectiveness
This pattern increases litigation flexibility. It is easier for a patentee to select the most favorable asserted claims after seeing the competitor’s label, formulation specs, and concentration.
What patent landscape questions can be answered from claims alone?
Without additional bibliographic and prosecution data, the landscape cannot be exhaustively mapped (for example: identifying related continuation patents, earlier priority art, family members, or co-pending litigation). The claim text you provided supports only infringement-scope analysis, not a complete “who owns what” landscape. Still, the claims imply the main competitive vectors:
- Single-agent topical active using the same chemical
- Single-agent topical treatment framed to ectoparasites
- Combination products with a conventional ectoparasiticide that claims activity on nymphs/adults
- Scalp-directed shampoo/lotion products
Key Takeaways
- US 9,357,783 is anchored on 5,5′-dimethyl-2,2′-dipyridyl (or acceptable salts) in topically applied compositions across a closed list of dosage forms including shampoo and lotion.
- The claim set creates multiple enforceable paths: broad topical composition (claim 1), skin/scalp targeting (claims 2–3), numeric concentration windows (claims 5–8 and 14–16), treat/prevent ectoparasite infestation (claim 12), and combination with a second ectoparasiticide with nymph/adult control (claims 9–10).
- Competitive design-around is most feasible by breaking at least one structural element: active/salt inclusion, dosage-form category, concentration windows (for dependent claims), combination structure (for claim 9), and the asserted treatment/scalp targeting limitations.
FAQs
Does US 9,357,783 cover sprays and aerosols, not just lotions and shampoos?
Yes. Claim 1 explicitly includes spray and aerosol among the enumerated topical forms.
Is the concentration range required for every infringement theory under US 9,357,783?
No. Claim 1, as provided, does not require a concentration window. Numeric concentration limitations appear only in dependent claims (5–8 for claim 1 and 14–16 for claim 12).
What makes claim 10 different from a generic combination claim?
Claim 10 requires that the second ectoparasiticide controls nymphs and/or adult ectoparasites, adding a functional biological stage limitation.
Can a competitor avoid infringement by targeting only veterinary uses?
Claim language includes veterinary acceptable salts, so veterinary targeting does not eliminate core coverage if the product still meets the claim structure (topical form, active/salt, and applicable dependent limitations).
Are shampoos and lotions treated as separate claim options or a subcategory?
They are explicitly called out in dependent claims:
- shampoo/lotion direct topical application appears in claim 4 (dependent on claim 1),
- and in claim 11 (dependent on claim 9) and claim 13 (dependent on claim 12).
